Iovance Biotherapeutics Affirms 2026 Revenue Guidance
Iovance Biotherapeutics updated its corporate presentation and reaffirmed its full-year 2026 revenue guidance of $410 million to $420 million.
Iovance Biotherapeutics updated its corporate presentation and reaffirmed its full-year 2026 revenue guidance of $410 million to $420 million.